Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 1;18(7):1412.
doi: 10.3390/ijms18071412.

Natural Compounds from Herbs that can Potentially Execute as Autophagy Inducers for Cancer Therapy

Shian-Ren Lin  1 , Yaw-Syan Fu  2 , May-Jywan Tsai  3   4 , Henrich Cheng  5   6 , Ching-Feng Weng  7
Affiliations
Review

Natural Compounds from Herbs that can Potentially Execute as Autophagy Inducers for Cancer Therapy

Shian-Ren Lin et al. Int J Mol Sci. .

Abstract

Accumulated evidence indicates that autophagy is a response of cancer cells to various anti-cancer therapies. Autophagy is designated as programmed cell death type II, and is characterized by the formation of autophagic vacuoles in the cytoplasm. Numerous herbs, including Chinese herbs, have been applied to cancer treatments as complementary and alternative medicines, supplements, or nutraceuticals to dampen the side or adverse effects of chemotherapy drugs. Moreover, the tumor suppressive actions of herbs and natural products induced autophagy that may lead to cell senescence, increase apoptosis-independent cell death or complement apoptotic processes. Hereby, the underlying mechanisms of natural autophagy inducers are cautiously reviewed in this article. Additionally, three natural compounds-curcumin, 16-hydroxycleroda-3,13-dien-15,16-olide, and prodigiosin-are presented as candidates for autophagy inducers that can trigger cell death in a supplement or alternative medicine for cancer therapy. Despite recent advancements in therapeutic drugs or agents of natural products in several cancers, it warrants further investigation in preclinical and clinical studies.

Keywords: autophagy inducer; autophagy inhibitor; cancer therapy; natural compound.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bast R.C. Cardinal manifestations of cancer. In: Holland J.F., Hong W.K., Kufe D.W., Bast R.C. Jr., Hait W.N., Pollock R.E., Weichselbaum R.R., editors. Holland-Frei Cancer Medicine. 9th ed. John Wiley & Sons, Inc.; Hoboken, NJ, USA: 2016. pp. 3–7.
    1. Disease G.B.D., Injury I., Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–1602. - PMC - PubMed
    1. Stewart B.W., Wild C. World Cancer Report 2014. International Agency for Research on Cancer, WHO Press; Lyon, France: Geneva, Switzerland: 2014.
    1. Feigin V., GBD 2015 Mortality. Causes of Death Collaborators Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1459–1544. - PMC - PubMed
    1. Von Hoff D.D., Hanauske A.R. Preclinical and early clinical development of chemotherapeutic drugs, mechanism-based agents and biologics. In: Hong K.W., Kufe D.W., Bast R.C. Jr., Hait W., Pollock R.E., Weichselbaum R.R., Holland J.F., Frei E. III, editors. Holland-Frei Cancer Medicine. 8th ed. People’s Medical Publishing House-USA; Shelton, CT, USA: 2010. pp. 568–587.

LinkOut - more resources